Perth, Nov 2, 2007 AEST (ABN Newswire) - HELICON GROUP LIMITED (ASX code: HCG) announced the release of its 2007 Annual Report, the first as a publicly listed company.
The report is available on the Helicon Group website:
http://www.helicongroup.com.au
Helicon is a speciality pharmaceutical marketing company that takes proven proprietary products and drives their market value growth in China, the world's fastest growing pharmaceutical market.
China's Pharmaceutical Market is valued at US$14billion is expected to rank in the top 5 globally by 2010 (BCG China Report 2005)
COMPANY STRATEGY
- Helicon is positioned to be the vehicle of choice into top tier hospitals in China and other North Asian markets for small to medium sized Western research driven biomedical companies.
- Helicon identifies poorly met needs in China and obtains exclusive licenses for innovative products, proven and registered in the western jurisdictions.
- Helicon manages the regulatory approvals and distribution and logistics using established blue chip market partners.
- Helicon owns the relationships with key opinion leaders and decision makers through the deployment of its own dedicated sales and marketing team.
- Helicon has an experienced Board and Management with breadth and depth of experience to effectively execute its strategy.
Helicon is the vehicle of choice into top tier hospitals in China and North Asia for Western approved specialty pharmaceuticals developed by research driven SME's.
Contact
Peter Abrahamson
Helicon Group Limited
Level 1, 173 Mounts Bay Road Perth WA 6000
Tel: +61 411 336 330 (Australia)
Tel: +86 1366 147 9600 (China)
Email: peter@helicongroup.com.au
Website: www.helicongroup.com.au
| ||
|
